Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series

Digestive Diseases and Sciences

Volumn 60, Issue 4, 2015, Pages 951-956

  Kang, Yun Seong ^a   Moon, Hyoung Ho ^a   Lee, Seung Eun ^a   Lim, Yun Jeong ^a   Kang, Hyoun Woo ^a  

^a Dongguk University Ilsan Hospital   (South Korea)

Author keywords

Anti tumor necrosis factor alpha; Biosimilar; Inflammatory bowel disease; Infliximab

Indexed keywords

BIOSIMILAR AGENT; CT-P13; INFLIXIMAB; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84934294253     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3392-z     Document Type: Article

References (27)

1. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease—seven years on. Aliment Pharmacol Ther. 2006;23:451–463.
2. Norum J, Koldingsnes W, Aanes T, et al. The economic burden of TNFα inhibitors and other biologic treatments in Norway. ClinicoEconomics Outcomes Res (CEOR). 2011;3:73.
3. World Health Organization. WHO expert committee on biological standardization. World Health Organ Tech Rep Ser. 2013;978:1–384, back cover.
4. Kanase SJ, Gavhane YN, Khandekar A, et al. Biosimilar: an overview. Int J Pharm Sci Res. 2013;4:2132–2144.
5. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1:457–462.
6. Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol. 2009;6:550–552.
7. Generic Pharmaceutical Association. Savings achieved through the use of generic pharmaceuticals 2000–2009. http://www.gphaonline.org/sites/default/files/GPhA%20Savings%20Study%20Book%20Updated%20Web%20FINAL%20Jul23%2010_0.pdf. Accessed 12 May 2011.
8. Epstein MS, Ehrenpreis ED, Kulkarni PM. Biosimilars: the need, the challenge, the future: the FDA perspective. Am J Gastroenterol. 2014. doi:10.1038/ajg.2014.151.
9. Weise M, Bielsky M-C, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111–5117.
10. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620.
11. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612.
12. Dignass A, Van Assche G, Lindsay J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohn’s Colitis. 2010;4:28–62.
13. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations. Washington, DC: Food and Drug Administration; 2003.
14. Best WR, Becktel J, Singleton J, et al. Development of a Crohn’s disease activity index. Gastroenterology. 1976;70:439–444.
15. D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–786.
16. Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117:761–769.
17. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
18. Travis S, Dinesen L. Remission in trials of ulcerative colitis: what does it mean? Pract Gastroenterol. 2006;30:17.
19. Clark M, Colombel J-F, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology. 2007;133:312–339.
20. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997;337:1029–1036.
21. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.
22. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17:S176–S185.
23. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849–853.
24. Rutgeerts P, Feagan B, Olson A, et al. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: act 1 trial. Gastroenterology. 2005;128:A105.
25. Sandborn W, Reinisch W, Rachmilewitz D, et al. Infliximab induction and maintenance therapy for ulcerative colitis: the act 2 trial. Zeitschrift für Gastroenterologie. 2005;43:V6.
26. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol. 2000;95:3490–3497.
27. Colombel J-F, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19–31.